Insider · CIK 0001256230
Eran Broshy
directorother
Files at TBPH (Theravance Biopharma, Inc.), CERT (Certara, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2025 | CERT Certara, Inc. | MOption exercise Common Stock | +11,928 | $0.00 | $0 | 34,951 | May 22, 2025 |
| May 21, 2025 | CERT Certara, Inc. | MOption exercise Restricted Stock Unitsderivative | -11,928 | $0.00 | $0 | 0 | May 22, 2025 |
| May 21, 2025 | CERT Certara, Inc. | AGrant or award Restricted Stock Unitsderivative | +15,757 | $0.00 | $0 | 15,757 | May 22, 2025 |
| May 19, 2025 | TBPH Theravance Biopharma, Inc. | AGrant or award Ordinary Shares | +10,649 | $0.00 | $0 | 91,204 | May 21, 2025 |
| May 19, 2025 | TBPH Theravance Biopharma, Inc. | AGrant or award Share Option (Right to Buy)derivative | +24,258 | $0.00 | $0 | 24,258 | May 21, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.